Kala Pharmaceuticals

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Kala Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $114.4B in funding across 208 round(s). With a team of 101-250 employees, Kala Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Kala Pharmaceuticals, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.